Although the second quarter did not feature any life sciences enforcement action by the FTC, there was plenty of news in and around the space. The FTC held a detailed “virtual workshop” as part of its pharmaceutical...more
On July 9, 2021, President Joe Biden announced a broad executive order (the “Order”) intended to boost what it characterizes as stagnant competition across the U.S. economy. The Order, among other things, encourages the...more
7/15/2021
/ Acquisitions ,
Antitrust Division ,
Antitrust Provisions ,
Biden Administration ,
Biosimilars ,
Competition ,
Data Collection ,
Department of Justice (DOJ) ,
Emerging Technology Companies ,
Employee Benefits ,
Executive Orders ,
Federal Trade Commission (FTC) ,
Generic Drugs ,
Hart-Scott-Rodino Act ,
Health Care Providers ,
Health Insurance ,
Horizontal Mergers ,
Hospitals ,
Joint Statements ,
Licensing Rules ,
Merger Reviews ,
Mergers ,
Non-Compete Agreements ,
Online Marketplace ,
Pharmaceutical Industry ,
Prescription Drugs ,
Rulemaking Process ,
Surveillance ,
Technology Sector ,
Unfair Competition ,
Vertical Mergers ,
Wage and Hour